AU2005295654B2 - Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists - Google Patents
Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists Download PDFInfo
- Publication number
- AU2005295654B2 AU2005295654B2 AU2005295654A AU2005295654A AU2005295654B2 AU 2005295654 B2 AU2005295654 B2 AU 2005295654B2 AU 2005295654 A AU2005295654 A AU 2005295654A AU 2005295654 A AU2005295654 A AU 2005295654A AU 2005295654 B2 AU2005295654 B2 AU 2005295654B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- methyl
- dione
- amino
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000000034 method Methods 0.000 title claims description 85
- 208000036065 Airway Remodeling Diseases 0.000 title claims description 29
- 101150078577 Adora2b gene Proteins 0.000 title description 24
- 206010035664 Pneumonia Diseases 0.000 title description 24
- 229940121359 adenosine receptor antagonist Drugs 0.000 title description 19
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title description 19
- 241000124008 Mammalia Species 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 13
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 12
- KOYXXLLNCXWUNF-UHFFFAOYSA-N 3-ethyl-1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 KOYXXLLNCXWUNF-UHFFFAOYSA-N 0.000 claims description 10
- 230000002265 prevention Effects 0.000 claims description 7
- 238000007912 intraperitoneal administration Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 description 235
- -1 [1,2,4]-oxadiazol-3-yl Chemical group 0.000 description 107
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 96
- 241000699670 Mus sp. Species 0.000 description 90
- 238000002360 preparation method Methods 0.000 description 86
- 238000006243 chemical reaction Methods 0.000 description 84
- 102000055025 Adenosine deaminases Human genes 0.000 description 64
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 63
- 125000000217 alkyl group Chemical group 0.000 description 58
- 239000000203 mixture Substances 0.000 description 58
- 210000004072 lung Anatomy 0.000 description 54
- 125000001072 heteroaryl group Chemical group 0.000 description 47
- 125000001424 substituent group Chemical group 0.000 description 45
- 125000003118 aryl group Chemical group 0.000 description 43
- 239000000047 product Substances 0.000 description 41
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 38
- 239000003981 vehicle Substances 0.000 description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 35
- 238000011282 treatment Methods 0.000 description 33
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- 239000002904 solvent Substances 0.000 description 30
- 125000003545 alkoxy group Chemical group 0.000 description 28
- 230000002829 reductive effect Effects 0.000 description 28
- 229940123053 Adenosine A2b receptor antagonist Drugs 0.000 description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 23
- 229910052736 halogen Inorganic materials 0.000 description 23
- 150000002367 halogens Chemical class 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 125000004181 carboxyalkyl group Chemical group 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 22
- 125000004093 cyano group Chemical group *C#N 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 22
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 125000002947 alkylene group Chemical group 0.000 description 21
- 239000001257 hydrogen Substances 0.000 description 21
- 229910052739 hydrogen Inorganic materials 0.000 description 21
- 125000004432 carbon atom Chemical group C* 0.000 description 20
- 125000000623 heterocyclic group Chemical group 0.000 description 20
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 20
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 19
- 229960005305 adenosine Drugs 0.000 description 19
- 125000003342 alkenyl group Chemical group 0.000 description 19
- 230000000694 effects Effects 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- 150000001412 amines Chemical class 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 208000006673 asthma Diseases 0.000 description 17
- 125000000392 cycloalkenyl group Chemical group 0.000 description 17
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 17
- 125000000304 alkynyl group Chemical group 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 108010035532 Collagen Proteins 0.000 description 14
- 102000008186 Collagen Human genes 0.000 description 14
- 150000003857 carboxamides Chemical class 0.000 description 14
- 150000002431 hydrogen Chemical class 0.000 description 14
- NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 13
- 239000011734 sodium Substances 0.000 description 13
- 125000000547 substituted alkyl group Chemical group 0.000 description 13
- 238000000692 Student's t-test Methods 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000005557 antagonist Substances 0.000 description 12
- 239000003795 chemical substances by application Substances 0.000 description 12
- 229920001436 collagen Polymers 0.000 description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 12
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 11
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 11
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 125000004414 alkyl thio group Chemical group 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 229930194542 Keto Natural products 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 125000002252 acyl group Chemical group 0.000 description 9
- 125000004442 acylamino group Chemical group 0.000 description 9
- 125000004423 acyloxy group Chemical group 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 125000005110 aryl thio group Chemical group 0.000 description 9
- 125000004104 aryloxy group Chemical group 0.000 description 9
- 125000001246 bromo group Chemical group Br* 0.000 description 9
- 125000001309 chloro group Chemical group Cl* 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 230000002140 halogenating effect Effects 0.000 description 9
- 125000005553 heteroaryloxy group Chemical group 0.000 description 9
- 125000000468 ketone group Chemical group 0.000 description 9
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 9
- 150000003573 thiols Chemical class 0.000 description 9
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 8
- 125000000033 alkoxyamino group Chemical group 0.000 description 8
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 description 8
- 125000006598 aminocarbonylamino group Chemical group 0.000 description 8
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 8
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 235000011114 ammonium hydroxide Nutrition 0.000 description 8
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 8
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 8
- 230000006378 damage Effects 0.000 description 8
- 230000008021 deposition Effects 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 125000005368 heteroarylthio group Chemical group 0.000 description 8
- 125000004470 heterocyclooxy group Chemical group 0.000 description 8
- 125000004468 heterocyclylthio group Chemical group 0.000 description 8
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 8
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 229940044551 receptor antagonist Drugs 0.000 description 8
- 239000002464 receptor antagonist Substances 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- UBZZBQIXYQZVDV-UHFFFAOYSA-N 1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxylic acid Chemical compound C1=C(C(=O)O)C=NN1CC1=CC=CC(C(F)(F)F)=C1 UBZZBQIXYQZVDV-UHFFFAOYSA-N 0.000 description 7
- QHEMDIZENXAVRQ-UHFFFAOYSA-N 6-amino-1-ethylpyrimidine-2,4-dione Chemical compound CCN1C(N)=CC(=O)NC1=O QHEMDIZENXAVRQ-UHFFFAOYSA-N 0.000 description 7
- 125000004429 atom Chemical group 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 125000005017 substituted alkenyl group Chemical group 0.000 description 7
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 6
- 102000009346 Adenosine receptors Human genes 0.000 description 6
- 108050000203 Adenosine receptors Proteins 0.000 description 6
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 6
- 206010016654 Fibrosis Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- UNVYIXUCXYHAEA-UHFFFAOYSA-N NC1=C(C(N(CN1)C(C(C)=O)CC)=O)NC(=O)C1=NN(C=C1)CC1=CC(=CC=C1)C(F)(F)F Chemical compound NC1=C(C(N(CN1)C(C(C)=O)CC)=O)NC(=O)C1=NN(C=C1)CC1=CC(=CC=C1)C(F)(F)F UNVYIXUCXYHAEA-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000004761 fibrosis Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 150000002430 hydrocarbons Chemical group 0.000 description 6
- 239000012442 inert solvent Substances 0.000 description 6
- 125000002346 iodo group Chemical group I* 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 235000010288 sodium nitrite Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 125000003107 substituted aryl group Chemical group 0.000 description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 6
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- FPJMMVWPHPRAMW-UHFFFAOYSA-N 6-amino-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(N)NC1=O FPJMMVWPHPRAMW-UHFFFAOYSA-N 0.000 description 5
- 239000007983 Tris buffer Substances 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000000651 myofibroblast Anatomy 0.000 description 5
- PVWOIHVRPOBWPI-UHFFFAOYSA-N n-propyl iodide Chemical compound CCCI PVWOIHVRPOBWPI-UHFFFAOYSA-N 0.000 description 5
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 5
- 125000004076 pyridyl group Chemical group 0.000 description 5
- 229930195734 saturated hydrocarbon Natural products 0.000 description 5
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 4
- TXDXEUVACFAWQB-UHFFFAOYSA-N 5,6-diamino-1-ethyl-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C(N)=C(N)N(CC)C1=O TXDXEUVACFAWQB-UHFFFAOYSA-N 0.000 description 4
- HEXZSEOAILCDMD-UHFFFAOYSA-N 5,6-diamino-1-ethylpyrimidine-2,4-dione Chemical compound CCN1C(N)=C(N)C(=O)NC1=O HEXZSEOAILCDMD-UHFFFAOYSA-N 0.000 description 4
- YPSQTTRYMSZAGR-UHFFFAOYSA-N 6-amino-1-ethyl-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(N)N(CC)C1=O YPSQTTRYMSZAGR-UHFFFAOYSA-N 0.000 description 4
- JVNIERUYZGPSCA-UHFFFAOYSA-N 6-amino-1-ethyl-5-nitroso-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C(N=O)=C(N)N(CC)C1=O JVNIERUYZGPSCA-UHFFFAOYSA-N 0.000 description 4
- SHKJXAPOAVPNKW-UHFFFAOYSA-N 6-amino-1-ethyl-5-nitrosopyrimidine-2,4-dione Chemical compound CCN1C(N)=C(N=O)C(=O)NC1=O SHKJXAPOAVPNKW-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 208000019693 Lung disease Diseases 0.000 description 4
- 102000004264 Osteopontin Human genes 0.000 description 4
- 108010081689 Osteopontin Proteins 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 230000035508 accumulation Effects 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 239000003449 adenosine A2 receptor antagonist Substances 0.000 description 4
- 208000026935 allergic disease Diseases 0.000 description 4
- 230000007815 allergy Effects 0.000 description 4
- 210000001132 alveolar macrophage Anatomy 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- SPJDDRUDFQBAOY-UHFFFAOYSA-N n'-(3-ethyl-2,6-dioxo-1-propylpyrimidin-4-yl)-n,n-dimethylmethanimidamide Chemical compound CCCN1C(=O)C=C(N=CN(C)C)N(CC)C1=O SPJDDRUDFQBAOY-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000006187 pill Substances 0.000 description 4
- 239000002798 polar solvent Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 125000004426 substituted alkynyl group Chemical group 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- DRBZCXPJVFOQDO-UHFFFAOYSA-N 5,6-diamino-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)NC(N)=C(N)C1=O DRBZCXPJVFOQDO-UHFFFAOYSA-N 0.000 description 3
- GZLZRPNUDBIQBM-UHFFFAOYSA-N 6-amino-1-methylpyrimidine-2,4-dione Chemical compound CN1C(N)=CC(=O)NC1=O GZLZRPNUDBIQBM-UHFFFAOYSA-N 0.000 description 3
- LNDZXOWGUAIUBG-UHFFFAOYSA-N 6-aminouracil Chemical compound NC1=CC(=O)NC(=O)N1 LNDZXOWGUAIUBG-UHFFFAOYSA-N 0.000 description 3
- 101150046889 ADORA3 gene Proteins 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 3
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 3
- FVKPZGAIJRIYTI-UHFFFAOYSA-N N-[6-amino-4-oxo-3-(2-oxopentan-3-yl)-1,2-dihydropyrimidin-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxamide Chemical compound NC1=C(C(N(CN1)C(C(C)=O)CC)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)C(F)(F)F FVKPZGAIJRIYTI-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 3
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 3
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 3
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000003125 aqueous solvent Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000000732 arylene group Chemical group 0.000 description 3
- XSCHRSMBECNVNS-UHFFFAOYSA-N benzopyrazine Natural products N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000007885 bronchoconstriction Effects 0.000 description 3
- 230000001593 cAMP accumulation Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 150000001718 carbodiimides Chemical class 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000020411 cell activation Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 150000004820 halides Chemical class 0.000 description 3
- 125000004475 heteroaralkyl group Chemical group 0.000 description 3
- 125000005549 heteroarylene group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 3
- CKBHZDKYMHOLNJ-UHFFFAOYSA-N n'-(3-ethyl-2,6-dioxopyrimidin-4-yl)-n,n-dimethylmethanimidamide Chemical compound CCN1C(N=CN(C)C)=CC(=O)NC1=O CKBHZDKYMHOLNJ-UHFFFAOYSA-N 0.000 description 3
- OWYHXGREQUUBMW-UHFFFAOYSA-N n-(6-amino-1-ethyl-2,4-dioxopyrimidin-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-3-carboxamide Chemical compound O=C1NC(=O)N(CC)C(N)=C1NC(=O)C1=NN(CC=2C=C(C=CC=2)C(F)(F)F)C=C1 OWYHXGREQUUBMW-UHFFFAOYSA-N 0.000 description 3
- 150000004866 oxadiazoles Chemical class 0.000 description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 3
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 3
- 102000054765 polymorphisms of proteins Human genes 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000003586 protic polar solvent Substances 0.000 description 3
- 230000002685 pulmonary effect Effects 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- HFRXJVQOXRXOPP-UHFFFAOYSA-N thionyl bromide Chemical compound BrS(Br)=O HFRXJVQOXRXOPP-UHFFFAOYSA-N 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- 125000004505 1,2,4-oxadiazol-5-yl group Chemical group O1N=CN=C1* 0.000 description 2
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 2
- SEKFWEUZFWPIIW-UHFFFAOYSA-N 1-propyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 SEKFWEUZFWPIIW-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- RGSFBJFXDRCAQB-UHFFFAOYSA-N 3-ethyl-1-propyl-8-[1-(pyridin-2-ylmethyl)pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=N1 RGSFBJFXDRCAQB-UHFFFAOYSA-N 0.000 description 2
- HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- PSIJQVXIJHUQPJ-UHFFFAOYSA-N 5,6-diamino-1-methylpyrimidine-2,4-dione Chemical compound CN1C(N)=C(N)C(=O)NC1=O PSIJQVXIJHUQPJ-UHFFFAOYSA-N 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 2
- JLLYLQLDYORLBB-UHFFFAOYSA-N 5-bromo-n-methylthiophene-2-sulfonamide Chemical compound CNS(=O)(=O)C1=CC=C(Br)S1 JLLYLQLDYORLBB-UHFFFAOYSA-N 0.000 description 2
- AHOWVSJPUQTRNN-UHFFFAOYSA-N 6-amino-1-methyl-5-nitrosopyrimidine-2,4-dione Chemical compound CN1C(N)=C(N=O)C(=O)NC1=O AHOWVSJPUQTRNN-UHFFFAOYSA-N 0.000 description 2
- MSYYROWSVFIBSJ-UHFFFAOYSA-N 6-amino-5-nitroso-3-propyl-1h-pyrimidine-2,4-dione Chemical compound CCCN1C(=O)NC(N)=C(N=O)C1=O MSYYROWSVFIBSJ-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 101150051188 Adora2a gene Proteins 0.000 description 2
- 108700028369 Alleles Proteins 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100023698 C-C motif chemokine 17 Human genes 0.000 description 2
- 108010012236 Chemokines Proteins 0.000 description 2
- 102000019034 Chemokines Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 102100023688 Eotaxin Human genes 0.000 description 2
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000978362 Homo sapiens C-C motif chemokine 17 Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 208000004852 Lung Injury Diseases 0.000 description 2
- 102100027998 Macrophage metalloelastase Human genes 0.000 description 2
- 101710187853 Macrophage metalloelastase Proteins 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- JTTYIGNOWNZSHC-UHFFFAOYSA-N N-[6-amino-4-oxo-3-(2-oxopropyl)-1,2-dihydropyrimidin-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxamide Chemical compound NC1=C(C(N(CN1)CC(C)=O)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)C(F)(F)F JTTYIGNOWNZSHC-UHFFFAOYSA-N 0.000 description 2
- XYRAUSDCUMGMLR-UHFFFAOYSA-N NC1=C(C(N(CN1)C(C(C)=O)C)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)C(F)(F)F Chemical compound NC1=C(C(N(CN1)C(C(C)=O)C)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)C(F)(F)F XYRAUSDCUMGMLR-UHFFFAOYSA-N 0.000 description 2
- RJSWPXDKRQVFLT-UHFFFAOYSA-N NC1=C(C(N(CN1)C(C=O)C)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)F Chemical compound NC1=C(C(N(CN1)C(C=O)C)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)F RJSWPXDKRQVFLT-UHFFFAOYSA-N 0.000 description 2
- GGBGCGMISMBOOG-UHFFFAOYSA-N O=C1C(C)C1CN1C(N)=C(NC(=O)C2=CN(CC=3C=C(C=CC=3)C#N)N=C2)C(=O)NC1 Chemical compound O=C1C(C)C1CN1C(N)=C(NC(=O)C2=CN(CC=3C=C(C=CC=3)C#N)N=C2)C(=O)NC1 GGBGCGMISMBOOG-UHFFFAOYSA-N 0.000 description 2
- MTEWHPAHLXBYGT-UHFFFAOYSA-N O=C1C(C)C1CN1C(N)=C(NC(=O)C2=CN(CC=3C=C(C=CC=3)C(F)(F)F)N=C2)C(=O)NC1 Chemical compound O=C1C(C)C1CN1C(N)=C(NC(=O)C2=CN(CC=3C=C(C=CC=3)C(F)(F)F)N=C2)C(=O)NC1 MTEWHPAHLXBYGT-UHFFFAOYSA-N 0.000 description 2
- XVYJSYLNJXYHBE-UHFFFAOYSA-N O=C1C(C)C1CN1C(N)=C(NC(=O)C2=CN(CC=3C=C(F)C=CC=3)N=C2)C(=O)NC1 Chemical compound O=C1C(C)C1CN1C(N)=C(NC(=O)C2=CN(CC=3C=C(F)C=CC=3)N=C2)C(=O)NC1 XVYJSYLNJXYHBE-UHFFFAOYSA-N 0.000 description 2
- HSVACMRJIWMDCE-UHFFFAOYSA-N O=C1C(CC)C1CN1C(N)=C(NC(=O)C2=CN(CC=3C=C(F)C=CC=3)N=C2)C(=O)NC1 Chemical compound O=C1C(CC)C1CN1C(N)=C(NC(=O)C2=CN(CC=3C=C(F)C=CC=3)N=C2)C(=O)NC1 HSVACMRJIWMDCE-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- QQONPFPTGQHPMA-UHFFFAOYSA-N Propene Chemical group CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 101000780338 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) Adenosine deaminase 1 Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000007984 Tris EDTA buffer Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 208000037883 airway inflammation Diseases 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 2
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 239000011260 aqueous acid Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- SIQPXVQCUCHWDI-UHFFFAOYSA-N enprofylline Chemical compound O=C1NC(=O)N(CCC)C2=C1NC=N2 SIQPXVQCUCHWDI-UHFFFAOYSA-N 0.000 description 2
- 239000012055 enteric layer Substances 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- ZIUSEGSNTOUIPT-UHFFFAOYSA-N ethyl 2-cyanoacetate Chemical compound CCOC(=O)CC#N ZIUSEGSNTOUIPT-UHFFFAOYSA-N 0.000 description 2
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- PQNFLJBBNBOBRQ-UHFFFAOYSA-N indane Chemical compound C1=CC=C2CCCC2=C1 PQNFLJBBNBOBRQ-UHFFFAOYSA-N 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- HTNWWUDAUHOYJH-UHFFFAOYSA-N n-[4-amino-1-(cyclopropylmethyl)-3-ethyl-2,6-dioxopyrimidin-5-yl]-1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyrazole-4-carboxamide Chemical compound O=C1N(CC2CC2)C(=O)N(CC)C(N)=C1NC(=O)C(=C1)C=NN1CC1=CC=C(C(F)(F)F)N=C1 HTNWWUDAUHOYJH-UHFFFAOYSA-N 0.000 description 2
- YIEZEHNAWUCRIL-UHFFFAOYSA-N n-[4-amino-1-(cyclopropylmethyl)-3-methyl-2,6-dioxopyrimidin-5-yl]-1-benzylpyrazole-4-carboxamide Chemical compound O=C1N(CC2CC2)C(=O)N(C)C(N)=C1NC(=O)C(=C1)C=NN1CC1=CC=CC=C1 YIEZEHNAWUCRIL-UHFFFAOYSA-N 0.000 description 2
- FMOMWNDPGNIBFR-UHFFFAOYSA-N n-[6-amino-1-ethyl-3-(2-methylpropyl)-2,4-dioxopyrimidin-5-yl]-1-[(3-fluorophenyl)methyl]pyrazole-4-carboxamide Chemical compound O=C1N(CC(C)C)C(=O)N(CC)C(N)=C1NC(=O)C1=CN(CC=2C=C(F)C=CC=2)N=C1 FMOMWNDPGNIBFR-UHFFFAOYSA-N 0.000 description 2
- HUZMXAGCTOAGNF-UHFFFAOYSA-N n-[6-amino-1-ethyl-3-(2-methylpropyl)-2,4-dioxopyrimidin-5-yl]-1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyrazole-4-carboxamide Chemical compound O=C1N(CC(C)C)C(=O)N(CC)C(N)=C1NC(=O)C1=CN(CC=2C=NC(=CC=2)C(F)(F)F)N=C1 HUZMXAGCTOAGNF-UHFFFAOYSA-N 0.000 description 2
- CSPNHBYQJGAJLJ-UHFFFAOYSA-N n-[6-amino-1-methyl-3-(2-methylpropyl)-2,4-dioxopyrimidin-5-yl]-1-[(3-fluorophenyl)methyl]pyrazole-4-carboxamide Chemical compound CN1C(=O)N(CC(C)C)C(=O)C(NC(=O)C2=CN(CC=3C=C(F)C=CC=3)N=C2)=C1N CSPNHBYQJGAJLJ-UHFFFAOYSA-N 0.000 description 2
- RCMGKGPGMQZEOD-UHFFFAOYSA-N n-[6-amino-1-methyl-3-(2-methylpropyl)-2,4-dioxopyrimidin-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxamide Chemical compound CN1C(=O)N(CC(C)C)C(=O)C(NC(=O)C2=CN(CC=3C=C(C=CC=3)C(F)(F)F)N=C2)=C1N RCMGKGPGMQZEOD-UHFFFAOYSA-N 0.000 description 2
- HEKXXGPQUCZPNE-UHFFFAOYSA-N n-[6-amino-1-methyl-3-(2-methylpropyl)-2,4-dioxopyrimidin-5-yl]-1-benzylpyrazole-4-carboxamide Chemical compound CN1C(=O)N(CC(C)C)C(=O)C(NC(=O)C2=CN(CC=3C=CC=CC=3)N=C2)=C1N HEKXXGPQUCZPNE-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002206 pro-fibrotic effect Effects 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 125000005156 substituted alkylene group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 150000003462 sulfoxides Chemical class 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 2
- 229920002554 vinyl polymer Polymers 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 125000001766 1,2,4-oxadiazol-3-yl group Chemical group [H]C1=NC(*)=NO1 0.000 description 1
- BBVIDBNAYOIXOE-UHFFFAOYSA-N 1,2,4-oxadiazole Chemical compound C=1N=CON=1 BBVIDBNAYOIXOE-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- FKASFBLJDCHBNZ-UHFFFAOYSA-N 1,3,4-oxadiazole Chemical compound C1=NN=CO1 FKASFBLJDCHBNZ-UHFFFAOYSA-N 0.000 description 1
- MBIZXFATKUQOOA-UHFFFAOYSA-N 1,3,4-thiadiazole Chemical compound C1=NN=CS1 MBIZXFATKUQOOA-UHFFFAOYSA-N 0.000 description 1
- MJVIGUCNSRXAFO-UHFFFAOYSA-N 1,3-dipropyl-7h-purine-2,6-dione Chemical compound O=C1N(CCC)C(=O)N(CCC)C2=C1NC=N2 MJVIGUCNSRXAFO-UHFFFAOYSA-N 0.000 description 1
- FJOWCRNUYDSBQY-UHFFFAOYSA-N 1,3-dipropyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C=1C=NNC=1 FJOWCRNUYDSBQY-UHFFFAOYSA-N 0.000 description 1
- NNBVIKCVEVSEMX-UHFFFAOYSA-N 1,3-dipropyl-8-[1-[[3-(2h-tetrazol-5-yl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC(C=1)=CC=CC=1C1=NN=NN1 NNBVIKCVEVSEMX-UHFFFAOYSA-N 0.000 description 1
- YTNFLFXQFWBCKN-UHFFFAOYSA-N 1,3-dipropyl-8-[1-[[5-[4-(trifluoromethyl)phenyl]-1,2-oxazol-3-yl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC(=NO1)C=C1C1=CC=C(C(F)(F)F)C=C1 YTNFLFXQFWBCKN-UHFFFAOYSA-N 0.000 description 1
- MYYYZNVAUZVXBO-UHFFFAOYSA-N 1-(bromomethyl)-3-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=CC(CBr)=C1 MYYYZNVAUZVXBO-UHFFFAOYSA-N 0.000 description 1
- UVHMEKJMMZTAPE-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-ethyl-8-[1-[[3-(trifluoromethyl)phenyl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(C3=CN(CC=4C=C(C=CC=4)C(F)(F)F)N=C3)NC=2C(=O)N1CC1CC1 UVHMEKJMMZTAPE-UHFFFAOYSA-N 0.000 description 1
- FOPDIVBIDYTGMD-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-ethyl-8-[1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound O=C1N(CC)C=2N=C(C3=CN(CC=4C=NC(=CC=4)C(F)(F)F)N=C3)NC=2C(=O)N1CC1CC1 FOPDIVBIDYTGMD-UHFFFAOYSA-N 0.000 description 1
- RSVMFPBVHDBXQE-UHFFFAOYSA-N 1-(cyclopropylmethyl)-3-methyl-8-[1-[2-(2h-tetrazol-5-yl)ethyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(C3=CN(CCC=4NN=NN=4)N=C3)NC=2C(=O)N1CC1CC1 RSVMFPBVHDBXQE-UHFFFAOYSA-N 0.000 description 1
- DOTYCWXTUKFRHZ-UHFFFAOYSA-N 1-(cyclopropylmethyl)-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3-methyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(C3=CN(CC=4C=C(F)C=CC=4)N=C3)NC=2C(=O)N1CC1CC1 DOTYCWXTUKFRHZ-UHFFFAOYSA-N 0.000 description 1
- JBGRNTKBOQPADE-UHFFFAOYSA-N 1-butyl-8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 JBGRNTKBOQPADE-UHFFFAOYSA-N 0.000 description 1
- MYEOAOVDIBWJEL-UHFFFAOYSA-N 1-butyl-8-[1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyrazol-4-yl]-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCCC)C(=O)NC=2N=C1C(=C1)C=NN1CC1=CC=C(C(F)(F)F)N=C1 MYEOAOVDIBWJEL-UHFFFAOYSA-N 0.000 description 1
- GQNHARINTUWVGG-UHFFFAOYSA-N 1-ethoxy-2-(2-ethoxyethoxy)ethane Chemical compound [CH2]COCCOCCOCC GQNHARINTUWVGG-UHFFFAOYSA-N 0.000 description 1
- OFQXVHPYWBHEMD-UHFFFAOYSA-N 1-phenyl-3,7-dihydropurine-2,6-dione Chemical compound O=C1NC=2N=CNC=2C(=O)N1C1=CC=CC=C1 OFQXVHPYWBHEMD-UHFFFAOYSA-N 0.000 description 1
- WJFKNYWRSNBZNX-UHFFFAOYSA-N 10H-phenothiazine Chemical compound C1=CC=C2NC3=CC=CC=C3SC2=C1 WJFKNYWRSNBZNX-UHFFFAOYSA-N 0.000 description 1
- TZMSYXZUNZXBOL-UHFFFAOYSA-N 10H-phenoxazine Chemical compound C1=CC=C2NC3=CC=CC=C3OC2=C1 TZMSYXZUNZXBOL-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- ZABMHLDQFJHDSC-UHFFFAOYSA-N 2,3-dihydro-1,3-oxazole Chemical compound C1NC=CO1 ZABMHLDQFJHDSC-UHFFFAOYSA-N 0.000 description 1
- VEPOHXYIFQMVHW-XOZOLZJESA-N 2,3-dihydroxybutanedioic acid (2S,3S)-3,4-dimethyl-2-phenylmorpholine Chemical compound OC(C(O)C(O)=O)C(O)=O.C[C@H]1[C@@H](OCCN1C)c1ccccc1 VEPOHXYIFQMVHW-XOZOLZJESA-N 0.000 description 1
- HBJUQLMVCIEESP-UHFFFAOYSA-N 2,5-dihydro-1,2,4-oxadiazole Chemical compound C1NC=NO1 HBJUQLMVCIEESP-UHFFFAOYSA-N 0.000 description 1
- UDNGNWOKQLQPJV-UHFFFAOYSA-N 2-[4-[6-oxo-1-(2-oxopropyl)-3-propyl-2,7-dihydropurin-8-yl]-1H-pyrazol-5-yl]-2-phenylacetic acid Chemical compound O=C(CN1CN(C=2N=C(NC=2C1=O)C=1C(=NNC=1)C(C(=O)O)C1=CC=CC=C1)CCC)C UDNGNWOKQLQPJV-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- AUVALWUPUHHNQV-UHFFFAOYSA-N 2-hydroxy-3-propylbenzoic acid Chemical class CCCC1=CC=CC(C(O)=O)=C1O AUVALWUPUHHNQV-UHFFFAOYSA-N 0.000 description 1
- VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- AZIMJLTVUFLESS-UHFFFAOYSA-N 3-[[4-(2,6-dioxo-1,3-dipropyl-7h-purin-8-yl)-1h-pyrazol-5-yl]methyl]benzoic acid Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C1=CNN=C1CC1=CC=CC(C(O)=O)=C1 AZIMJLTVUFLESS-UHFFFAOYSA-N 0.000 description 1
- QDZBSWAJFAAMPR-UHFFFAOYSA-N 3-[[4-[1-(cyclopropylmethyl)-3-methyl-2,6-dioxo-7h-purin-8-yl]-1h-pyrazol-5-yl]methyl]benzonitrile Chemical compound O=C1N(C)C=2N=C(C=3C(=NNC=3)CC=3C=C(C=CC=3)C#N)NC=2C(=O)N1CC1CC1 QDZBSWAJFAAMPR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FSZJGDMXEQVTPM-UHFFFAOYSA-N 3-butan-2-yl-1-methyl-8-(1h-pyrazol-4-yl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(C)C(=O)N(C(C)CC)C=2N=C1C=1C=NNC=1 FSZJGDMXEQVTPM-UHFFFAOYSA-N 0.000 description 1
- UWWGEIHSFZWTAF-UHFFFAOYSA-N 3-ethyl-1-(2-methylpropyl)-8-[1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=C(C(F)(F)F)N=C1 UWWGEIHSFZWTAF-UHFFFAOYSA-N 0.000 description 1
- TXEFUDYEMBGBMN-UHFFFAOYSA-N 3-ethyl-1-propyl-8-[1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]pyrazol-4-yl]-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC1=CC=C(C(F)(F)F)N=C1 TXEFUDYEMBGBMN-UHFFFAOYSA-N 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- VPTFNKJPILJQAO-UHFFFAOYSA-N 5,6-diamino-1-ethyl-3-(2-methylpropyl)pyrimidine-2,4-dione Chemical compound CCN1C(N)=C(N)C(=O)N(CC(C)C)C1=O VPTFNKJPILJQAO-UHFFFAOYSA-N 0.000 description 1
- PTMILWDITIQZMO-UHFFFAOYSA-N 5,6-diamino-1-methyl-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C(N)=C(N)N(C)C1=O PTMILWDITIQZMO-UHFFFAOYSA-N 0.000 description 1
- RJJKHZZQSNCHQV-UHFFFAOYSA-N 5,6-diamino-3-(2-methylpropyl)-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)NC(N)=C(N)C1=O RJJKHZZQSNCHQV-UHFFFAOYSA-N 0.000 description 1
- IOLMYZCGFXLRBE-UHFFFAOYSA-N 5,6-diamino-3-(cyclopropylmethyl)-1-methylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(N)=C(N)C(=O)N1CC1CC1 IOLMYZCGFXLRBE-UHFFFAOYSA-N 0.000 description 1
- OJDXACZTKUCFIP-UHFFFAOYSA-N 5,6-diamino-3-(cyclopropylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N)=C(N)NC(=O)N1CC1CC1 OJDXACZTKUCFIP-UHFFFAOYSA-N 0.000 description 1
- VTQUMHQRFOJNCR-UHFFFAOYSA-N 6-amino-1-ethyl-3-(2-methylpropyl)-5-nitrosopyrimidine-2,4-dione Chemical compound CCN1C(N)=C(N=O)C(=O)N(CC(C)C)C1=O VTQUMHQRFOJNCR-UHFFFAOYSA-N 0.000 description 1
- MYTJBSGNUVNQEN-UHFFFAOYSA-N 6-amino-1-ethyl-3-(2-methylpropyl)pyrimidine-2,4-dione Chemical compound CCN1C(N)=CC(=O)N(CC(C)C)C1=O MYTJBSGNUVNQEN-UHFFFAOYSA-N 0.000 description 1
- MJDFXQOIYKNUNZ-UHFFFAOYSA-N 6-amino-1-methyl-3-(2-methylpropyl)-5-nitrosopyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)C(N=O)=C(N)N(C)C1=O MJDFXQOIYKNUNZ-UHFFFAOYSA-N 0.000 description 1
- CLFDZWQFQJGVRN-UHFFFAOYSA-N 6-amino-1-methyl-3-(2-methylpropyl)pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)C=C(N)N(C)C1=O CLFDZWQFQJGVRN-UHFFFAOYSA-N 0.000 description 1
- OIHHBESCFLISMR-UHFFFAOYSA-N 6-amino-1-methyl-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C=C(N)N(C)C1=O OIHHBESCFLISMR-UHFFFAOYSA-N 0.000 description 1
- VMNWYLSOJUGKAC-UHFFFAOYSA-N 6-amino-1-methyl-5-nitroso-3-propylpyrimidine-2,4-dione Chemical compound CCCN1C(=O)C(N=O)=C(N)N(C)C1=O VMNWYLSOJUGKAC-UHFFFAOYSA-N 0.000 description 1
- HULCQAAULJKYCZ-UHFFFAOYSA-N 6-amino-3-(2-methylpropyl)-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)C=C(N)NC1=O HULCQAAULJKYCZ-UHFFFAOYSA-N 0.000 description 1
- DJHPWVGREQYVFM-UHFFFAOYSA-N 6-amino-3-(2-methylpropyl)-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound CC(C)CN1C(=O)NC(N)=C(N=O)C1=O DJHPWVGREQYVFM-UHFFFAOYSA-N 0.000 description 1
- FZENHJNRVJDKPO-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-1-ethyl-5-nitrosopyrimidine-2,4-dione Chemical compound O=C1N(CC)C(N)=C(N=O)C(=O)N1CC1CC1 FZENHJNRVJDKPO-UHFFFAOYSA-N 0.000 description 1
- RORUTZURFNBVKX-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-1-ethylpyrimidine-2,4-dione Chemical compound O=C1N(CC)C(N)=CC(=O)N1CC1CC1 RORUTZURFNBVKX-UHFFFAOYSA-N 0.000 description 1
- YRIVDAZOUJMIAH-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-1-methyl-5-nitrosopyrimidine-2,4-dione Chemical compound O=C1N(C)C(N)=C(N=O)C(=O)N1CC1CC1 YRIVDAZOUJMIAH-UHFFFAOYSA-N 0.000 description 1
- PYHNOZBKSUHFCO-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-1-methylpyrimidine-2,4-dione Chemical compound O=C1N(C)C(N)=CC(=O)N1CC1CC1 PYHNOZBKSUHFCO-UHFFFAOYSA-N 0.000 description 1
- CNGIDKXHQCZDRU-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-1h-pyrimidine-2,4-dione Chemical compound O=C1NC(N)=CC(=O)N1CC1CC1 CNGIDKXHQCZDRU-UHFFFAOYSA-N 0.000 description 1
- HEIJNQPNKGGRFM-UHFFFAOYSA-N 6-amino-3-(cyclopropylmethyl)-5-nitroso-1h-pyrimidine-2,4-dione Chemical compound O=C1C(N=O)=C(N)NC(=O)N1CC1CC1 HEIJNQPNKGGRFM-UHFFFAOYSA-N 0.000 description 1
- MNSIOYQSJGYMQS-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-1-(cyclopropylmethyl)-3-methyl-7h-purine-2,6-dione Chemical compound O=C1N(C)C=2N=C(C3=CN(CC=4C=CC=CC=4)N=C3)NC=2C(=O)N1CC1CC1 MNSIOYQSJGYMQS-UHFFFAOYSA-N 0.000 description 1
- MHPWKGIBRFKMRN-UHFFFAOYSA-N 8-(1-benzylpyrazol-4-yl)-3-methyl-1-(2-methylpropyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1 MHPWKGIBRFKMRN-UHFFFAOYSA-N 0.000 description 1
- INMYJCHAOZGGBA-UHFFFAOYSA-N 8-[1-(2-phenylethyl)pyrazol-4-yl]-1-propyl-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)NC=2N=C1C(=C1)C=NN1CCC1=CC=CC=C1 INMYJCHAOZGGBA-UHFFFAOYSA-N 0.000 description 1
- BXQRCUSBUDNKKE-UHFFFAOYSA-N 8-[1-[(2-methoxyphenyl)methyl]pyrazol-4-yl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(=C1)C=NN1CC1=CC=CC=C1OC BXQRCUSBUDNKKE-UHFFFAOYSA-N 0.000 description 1
- NAJBDLXZHBQZJD-UHFFFAOYSA-N 8-[1-[(3-fluorophenyl)methyl]pyrazol-4-yl]-3-methyl-1-(2-methylpropyl)-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CC(C)C)C(=O)N(C)C=2N=C1C(=C1)C=NN1CC1=CC=CC(F)=C1 NAJBDLXZHBQZJD-UHFFFAOYSA-N 0.000 description 1
- HWHLLTUJISZFDN-UHFFFAOYSA-N 8-[1-[[5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl]methyl]pyrazol-4-yl]-1-propyl-3,7-dihydropurine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)NC=2N=C1C(=C1)C=NN1CC(N=1)=NOC=1C1=CC=C(Cl)C=C1 HWHLLTUJISZFDN-UHFFFAOYSA-N 0.000 description 1
- PSHSAHVUUAGSSH-UHFFFAOYSA-N 8-[1-[[5-(4-chlorophenyl)-1,2-oxazol-3-yl]methyl]pyrazol-4-yl]-3-ethyl-1-propyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CC)C=2N=C1C(=C1)C=NN1CC(=NO1)C=C1C1=CC=C(Cl)C=C1 PSHSAHVUUAGSSH-UHFFFAOYSA-N 0.000 description 1
- JNJWKLSCJORTLT-UHFFFAOYSA-N 8-[4-[[5-(2-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC=C1OC JNJWKLSCJORTLT-UHFFFAOYSA-N 0.000 description 1
- AHJHSANRNGKAFS-UHFFFAOYSA-N 8-[4-[[5-(3-methoxyphenyl)-1,2,4-oxadiazol-3-yl]methoxy]phenyl]-1,3-dipropyl-7h-purine-2,6-dione Chemical compound N1C=2C(=O)N(CCC)C(=O)N(CCC)C=2N=C1C(C=C1)=CC=C1OCC(N=1)=NOC=1C1=CC=CC(OC)=C1 AHJHSANRNGKAFS-UHFFFAOYSA-N 0.000 description 1
- 101150061875 ADAM33 gene Proteins 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 102000007470 Adenosine A2B Receptor Human genes 0.000 description 1
- 108010085273 Adenosine A2B receptor Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010001889 Alveolitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical group C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 206010006448 Bronchiolitis Diseases 0.000 description 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 description 1
- PAOANWZGLPPROA-RQXXJAGISA-N CGS-21680 Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC(NCCC=3C=CC(CCC(O)=O)=CC=3)=NC(N)=C2N=C1 PAOANWZGLPPROA-RQXXJAGISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241001092081 Carpenteria Species 0.000 description 1
- 108010082548 Chemokine CCL11 Proteins 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108091006101 Gi proteins Proteins 0.000 description 1
- 102000034354 Gi proteins Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108091006065 Gs proteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 101100108123 Homo sapiens ADAM33 gene Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 206010054949 Metaplasia Diseases 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical class CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100398282 Mus musculus Kit gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 235000009421 Myristica fragrans Nutrition 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- JADDQZYHOWSFJD-FLNNQWSLSA-N N-ethyl-5'-carboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 JADDQZYHOWSFJD-FLNNQWSLSA-N 0.000 description 1
- HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- WXURXMQGECHFOR-UHFFFAOYSA-N NC1=C(C(N(CN1)CC(C)=O)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)C#N Chemical compound NC1=C(C(N(CN1)CC(C)=O)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)C#N WXURXMQGECHFOR-UHFFFAOYSA-N 0.000 description 1
- ATUUHEOEMZCYSO-UHFFFAOYSA-N NC1=C(C(N(CN1)CC(C)=O)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)F Chemical compound NC1=C(C(N(CN1)CC(C)=O)=O)NC(=O)C=1C=NN(C1)CC1=CC(=CC=C1)F ATUUHEOEMZCYSO-UHFFFAOYSA-N 0.000 description 1
- FZYJRJVBJWIOMQ-UHFFFAOYSA-N NC1=C(C(N(CN1)CC(C)=O)=O)NC(=O)C=1C=NN(C1)CC=1C=NC(=CC1)C(F)(F)F Chemical compound NC1=C(C(N(CN1)CC(C)=O)=O)NC(=O)C=1C=NN(C1)CC=1C=NC(=CC1)C(F)(F)F FZYJRJVBJWIOMQ-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- LLDQGBLEUUZBAA-UHFFFAOYSA-N O=C1N(CC2CC2)C(=O)N(C)C(N)=C1NC(=O)C(=C1)C=NN1CCC1=NN=NN1 Chemical compound O=C1N(CC2CC2)C(=O)N(C)C(N)=C1NC(=O)C(=C1)C=NN1CCC1=NN=NN1 LLDQGBLEUUZBAA-UHFFFAOYSA-N 0.000 description 1
- QOEQBBGHNKEYLX-UHFFFAOYSA-N O=C1NCN(CC2C(C2)=O)C(N)=C1NC(=O)C(=C1)C=NN1CC1=CC=C(C(F)(F)F)N=C1 Chemical compound O=C1NCN(CC2C(C2)=O)C(N)=C1NC(=O)C(=C1)C=NN1CC1=CC=C(C(F)(F)F)N=C1 QOEQBBGHNKEYLX-UHFFFAOYSA-N 0.000 description 1
- IBRGGMQXNNLFOP-UHFFFAOYSA-N O=C1NCN(CC2C(C2)=O)C(N)=C1NC(=O)C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 Chemical compound O=C1NCN(CC2C(C2)=O)C(N)=C1NC(=O)C(=C1)C=NN1CC1=CC=CC(C(F)(F)F)=C1 IBRGGMQXNNLFOP-UHFFFAOYSA-N 0.000 description 1
- JGPWWJRYKFRMQS-UHFFFAOYSA-N O=C1NCN(CC2C(C2)=O)C(N)=C1NC(=O)C(=C1)C=NN1CC1=CC=CC(F)=C1 Chemical compound O=C1NCN(CC2C(C2)=O)C(N)=C1NC(=O)C(=C1)C=NN1CC1=CC=CC(F)=C1 JGPWWJRYKFRMQS-UHFFFAOYSA-N 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108700020962 Peroxidase Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 101100545004 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) YSP2 gene Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 108700012920 TNF Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 210000005058 airway cell Anatomy 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 150000004982 aromatic amines Chemical class 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 125000002529 biphenylenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C12)* 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 238000013262 cAMP assay Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- WCZVZNOTHYJIEI-UHFFFAOYSA-N cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005265 dialkylamine group Chemical group 0.000 description 1
- 125000005266 diarylamine group Chemical group 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229950000579 enprofylline Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- MUZVVDZDMRMPPL-UHFFFAOYSA-N ethyl 1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxylate Chemical compound C1=C(C(=O)OCC)C=NN1CC1=CC=CC(C(F)(F)F)=C1 MUZVVDZDMRMPPL-UHFFFAOYSA-N 0.000 description 1
- KACZQOKEFKFNDB-UHFFFAOYSA-N ethyl 1h-pyrazole-4-carboxylate Chemical compound CCOC(=O)C=1C=NNC=1 KACZQOKEFKFNDB-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- WHRIKZCFRVTHJH-UHFFFAOYSA-N ethylhydrazine Chemical compound CCNN WHRIKZCFRVTHJH-UHFFFAOYSA-N 0.000 description 1
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000005241 heteroarylamino group Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GWNVDXQDILPJIG-NXOLIXFESA-N leukotriene C4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O GWNVDXQDILPJIG-NXOLIXFESA-N 0.000 description 1
- 239000011344 liquid material Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 239000001115 mace Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- DWCZIOOZPIDHAB-UHFFFAOYSA-L methyl green Chemical compound [Cl-].[Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC(=CC=1)[N+](C)(C)C)=C1C=CC(=[N+](C)C)C=C1 DWCZIOOZPIDHAB-UHFFFAOYSA-L 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- ZTCIYGJTEITPHU-UHFFFAOYSA-N n'-[1-(cyclopropylmethyl)-3-ethyl-2,6-dioxopyrimidin-4-yl]-n,n-dimethylmethanimidamide Chemical compound O=C1N(CC)C(N=CN(C)C)=CC(=O)N1CC1CC1 ZTCIYGJTEITPHU-UHFFFAOYSA-N 0.000 description 1
- VRBSPPGSXSZJOM-UHFFFAOYSA-N n'-[1-(cyclopropylmethyl)-3-methyl-2,6-dioxopyrimidin-4-yl]-n,n-dimethylmethanimidamide Chemical compound O=C1N(C)C(N=CN(C)C)=CC(=O)N1CC1CC1 VRBSPPGSXSZJOM-UHFFFAOYSA-N 0.000 description 1
- XIQLJOLVZIEXQG-UHFFFAOYSA-N n'-[3-ethyl-1-(2-methylpropyl)-2,6-dioxopyrimidin-4-yl]-n,n-dimethylmethanimidamide Chemical compound CCN1C(N=CN(C)C)=CC(=O)N(CC(C)C)C1=O XIQLJOLVZIEXQG-UHFFFAOYSA-N 0.000 description 1
- OEUCMWDVAXAROU-UHFFFAOYSA-N n,n-dimethyl-n'-(3-methyl-2,6-dioxo-1-propylpyrimidin-4-yl)methanimidamide Chemical compound CCCN1C(=O)C=C(N=CN(C)C)N(C)C1=O OEUCMWDVAXAROU-UHFFFAOYSA-N 0.000 description 1
- LKFHXQQCMWXMLN-UHFFFAOYSA-N n,n-dimethyl-n'-(3-methyl-2,6-dioxopyrimidin-4-yl)methanimidamide Chemical compound CN(C)C=NC1=CC(=O)NC(=O)N1C LKFHXQQCMWXMLN-UHFFFAOYSA-N 0.000 description 1
- AKYPPFJFHWLTSM-UHFFFAOYSA-N n,n-dimethyl-n'-[3-methyl-1-(2-methylpropyl)-2,6-dioxopyrimidin-4-yl]methanimidamide Chemical compound CC(C)CN1C(=O)C=C(N=CN(C)C)N(C)C1=O AKYPPFJFHWLTSM-UHFFFAOYSA-N 0.000 description 1
- SYZRCDDKRGGITN-UHFFFAOYSA-N n-(6-amino-1-ethyl-2,4-dioxopyrimidin-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxamide Chemical compound O=C1NC(=O)N(CC)C(N)=C1NC(=O)C1=CN(CC=2C=C(C=CC=2)C(F)(F)F)N=C1 SYZRCDDKRGGITN-UHFFFAOYSA-N 0.000 description 1
- CZIXMRTVTASRHB-UHFFFAOYSA-N n-(6-amino-1-methyl-2,4-dioxopyrimidin-5-yl)-1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxamide Chemical compound O=C1NC(=O)N(C)C(N)=C1NC(=O)C1=CN(CC=2C=C(C=CC=2)C(F)(F)F)N=C1 CZIXMRTVTASRHB-UHFFFAOYSA-N 0.000 description 1
- LBGMQFSBCOQXGL-UHFFFAOYSA-N n-[6-amino-3-(2-methylpropyl)-2,4-dioxo-1h-pyrimidin-5-yl]-1-[(3-cyanophenyl)methyl]pyrazole-4-carboxamide Chemical compound O=C1N(CC(C)C)C(=O)NC(N)=C1NC(=O)C1=CN(CC=2C=C(C=CC=2)C#N)N=C1 LBGMQFSBCOQXGL-UHFFFAOYSA-N 0.000 description 1
- AUXOIJGBTGPMBW-UHFFFAOYSA-N n-[6-amino-3-(2-methylpropyl)-2,4-dioxo-1h-pyrimidin-5-yl]-1-[(3-fluorophenyl)methyl]pyrazole-4-carboxamide Chemical compound O=C1N(CC(C)C)C(=O)NC(N)=C1NC(=O)C1=CN(CC=2C=C(F)C=CC=2)N=C1 AUXOIJGBTGPMBW-UHFFFAOYSA-N 0.000 description 1
- CVZHXZVTOBLXCF-UHFFFAOYSA-N n-[6-amino-3-(2-methylpropyl)-2,4-dioxo-1h-pyrimidin-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]pyrazole-4-carboxamide Chemical compound O=C1N(CC(C)C)C(=O)NC(N)=C1NC(=O)C1=CN(CC=2C=C(C=CC=2)C(F)(F)F)N=C1 CVZHXZVTOBLXCF-UHFFFAOYSA-N 0.000 description 1
- HGUZQMQXAHVIQC-UHFFFAOYSA-N n-methylethenamine Chemical group CNC=C HGUZQMQXAHVIQC-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- UMRZSTCPUPJPOJ-KNVOCYPGSA-N norbornane Chemical compound C1C[C@H]2CC[C@@H]1C2 UMRZSTCPUPJPOJ-KNVOCYPGSA-N 0.000 description 1
- JFNLZVQOOSMTJK-KNVOCYPGSA-N norbornene Chemical compound C1[C@@H]2CC[C@H]1C=C2 JFNLZVQOOSMTJK-KNVOCYPGSA-N 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229950000688 phenothiazine Drugs 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- CPNGPNLZQNNVQM-UHFFFAOYSA-N pteridine Chemical compound N1=CN=CC2=NC=CN=C21 CPNGPNLZQNNVQM-UHFFFAOYSA-N 0.000 description 1
- 210000004879 pulmonary tissue Anatomy 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical class [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 description 1
- 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 150000003254 radicals Chemical group 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
- 238000012385 systemic delivery Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 229960004559 theobromine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 125000005270 trialkylamine group Chemical group 0.000 description 1
- 125000005259 triarylamine group Chemical group 0.000 description 1
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61943904P | 2004-10-15 | 2004-10-15 | |
| US60/619,439 | 2004-10-15 | ||
| PCT/US2005/036950 WO2006044610A1 (en) | 2004-10-15 | 2005-10-14 | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2005295654A1 AU2005295654A1 (en) | 2006-04-27 |
| AU2005295654B2 true AU2005295654B2 (en) | 2011-04-14 |
Family
ID=35677798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2005295654A Ceased AU2005295654B2 (en) | 2004-10-15 | 2005-10-14 | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20060159627A1 (enExample) |
| EP (2) | EP2311462A1 (enExample) |
| JP (2) | JP2008516969A (enExample) |
| KR (1) | KR20070063548A (enExample) |
| CN (1) | CN101039677A (enExample) |
| AU (1) | AU2005295654B2 (enExample) |
| CA (1) | CA2583986A1 (enExample) |
| IL (1) | IL182493A0 (enExample) |
| MX (1) | MX2007004373A (enExample) |
| NO (1) | NO20072466L (enExample) |
| NZ (2) | NZ589657A (enExample) |
| RU (1) | RU2391103C2 (enExample) |
| WO (1) | WO2006044610A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE47351E1 (en) | 1999-06-22 | 2019-04-16 | Gilead Sciences, Inc. | 2-(N-pyrazolo)adenosines with application as adenosine A2A receptor agonists |
| US6403567B1 (en) | 1999-06-22 | 2002-06-11 | Cv Therapeutics, Inc. | N-pyrazole A2A adenosine receptor agonists |
| AU2001238665A1 (en) | 2000-02-23 | 2001-09-03 | Cv Therapeutics, Inc. | Method of identifying partial agonists of the a2a receptor |
| WO2004011010A1 (en) * | 2002-07-29 | 2004-02-05 | Cv Therapeutics, Inc. | Myocardial perfusion imaging using a2a receptor agonists |
| CN1894250B (zh) * | 2003-08-25 | 2010-06-09 | PGx健康有限责任公司 | 取代的8-杂芳基黄嘌呤 |
| JP2008517063A (ja) * | 2004-10-20 | 2008-05-22 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ａアデノシンレセプターアゴニストの使用 |
| US7618962B2 (en) * | 2005-02-25 | 2009-11-17 | Pgx Health, Llc | Pyrazolyl substituted xanthines |
| WO2006091897A2 (en) * | 2005-02-25 | 2006-08-31 | Adenosine Therapeutics, Llc | Derivatives of 8-substituted xanthines |
| US7598379B2 (en) * | 2005-02-25 | 2009-10-06 | Pgx Health, Llc | Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines |
| US7625881B2 (en) * | 2005-06-16 | 2009-12-01 | Gilead Palo Alto, Inc. | Prodrugs of A2B adenosine receptor antagonists |
| US20090007281A1 (en) * | 2006-01-13 | 2009-01-01 | Battelle Memorial Institute | Animal Model for Assessing Copd-Related Diseases |
| PL1989214T3 (pl) | 2006-02-03 | 2017-07-31 | Gilead Sciences, Inc. | Proces otrzymywania agonisty receptora adenozynowego a2a i jego polimorfów |
| US7884100B2 (en) * | 2006-06-16 | 2011-02-08 | Pgxhealth, Llc | Substituted 8-[6-amino-3-pyridyl]xanthines |
| US7767685B2 (en) * | 2006-06-29 | 2010-08-03 | King Pharmaceuticals Research And Development, Inc. | Adenosine A2B receptor antagonists |
| KR20090047499A (ko) * | 2006-09-01 | 2009-05-12 | 씨브이 쎄러퓨틱스, 인코포레이티드 | 심근 조영법 동안에 환자의 순응성을 증가시키기 위한 방법및 조성물 |
| US20090081120A1 (en) * | 2006-09-01 | 2009-03-26 | Cv Therapeutics, Inc. | Methods and Compositions for Increasing Patient Tolerability During Myocardial Imaging Methods |
| EP2066232A1 (en) * | 2006-09-29 | 2009-06-10 | Cv Therapeutics, Inc. | Methods for myocardial imaging in patients having a history of pulmonary disease |
| JP2010515081A (ja) * | 2007-01-03 | 2010-05-06 | ギリアード・パロ・アルト・インコーポレイテッド | 心筋灌流画像化 |
| CA2718983C (en) * | 2008-03-26 | 2015-12-08 | Advinus Therapeutics Pvt. Ltd. | Heterocyclic compounds as adenosine receptor antagonist |
| MX2011003168A (es) * | 2008-09-29 | 2011-05-19 | Gilead Sciences Inc | Combinaciones de un agente de control de cantidad y un antagonista del receptor a-2-alfa para utilizarse en metodos de tomografia computarizada de detectores multiples. |
| WO2010103547A2 (en) * | 2009-03-13 | 2010-09-16 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| EP2595630A1 (en) * | 2010-06-30 | 2013-05-29 | Gilead Sciences, Inc. | Use of a2b adenosine receptor antagonists for treating pulmonary hypertension |
| AR085942A1 (es) | 2011-04-07 | 2013-11-06 | Gilead Sciences Inc | Uso de receptor de aadenosina para tratar la insuficiencia cardiaca y la arritmia en pacientes posinfarto de miocardio |
| CN107249630A (zh) * | 2014-11-24 | 2017-10-13 | 国家健康与医学研究院 | 通过il‑20r的拮抗作用治疗慢性阻塞性肺疾病的急性加重 |
| ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| CN112218867B (zh) | 2018-03-05 | 2023-11-21 | 泰昂治疗公司 | 腺苷受体拮抗剂及其用途 |
| AU2021336911A1 (en) * | 2020-09-04 | 2023-03-16 | Teon Therapeutics, Inc. | Cocrystals of an adenosine A2B receptor antagonist |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030139428A1 (en) * | 2001-11-09 | 2003-07-24 | Rao Kalla | A2B adenosine receptor antagonists |
| US20030229103A1 (en) * | 2001-08-12 | 2003-12-11 | Klaus-Ulrich Weithmann | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases |
| US20040176399A1 (en) * | 2001-11-09 | 2004-09-09 | Elfatih Elzein | A2B adenosine receptor antagonists |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| US5854081A (en) | 1996-06-20 | 1998-12-29 | The University Of Patent Foundation | Stable expression of human A2B adenosine receptors, and assays employing the same |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| US6545002B1 (en) | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| US6815446B1 (en) | 1999-08-31 | 2004-11-09 | Vanderbilt University | Selective antagonists of A2B adenosine receptors |
| HK1049835B (zh) * | 1999-08-31 | 2005-04-08 | 范德比尔特大学 | A2b腺苷受体的选择性拮抗剂 |
| IL133680A0 (en) * | 1999-09-10 | 2001-04-30 | Can Fite Technologies Ltd | Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist |
| US6894021B2 (en) | 2000-02-17 | 2005-05-17 | Cv Therapeutics, Inc. | Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation |
| US6387913B1 (en) * | 2000-12-07 | 2002-05-14 | S. Jamal Mustafa | Method of treating airway diseases with combined administration of A2B and A3 adenosine receptor antagonists |
| US20030235555A1 (en) * | 2002-04-05 | 2003-12-25 | David Shealey | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses |
| US7304070B2 (en) | 2001-11-09 | 2007-12-04 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US20080318983A1 (en) | 2001-11-09 | 2008-12-25 | Rao Kalla | A2b adenosine receptor antagonists |
| US7317017B2 (en) | 2002-11-08 | 2008-01-08 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| US6977300B2 (en) * | 2001-11-09 | 2005-12-20 | Cv Therapeutics, Inc. | A2B adenosine receptor antagonists |
| EA007468B1 (ru) * | 2001-12-20 | 2006-10-27 | Оси Фармасьютикалз, Инк. | Пиримидиновые соединения, относящиеся к a-селективным антагонистам, их синтез и применение |
| ES2229928B1 (es) | 2003-10-02 | 2006-07-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirimidin-2-amina. |
| KR20060111467A (ko) | 2003-10-31 | 2006-10-27 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ2ｂ 아데노신 수용체 안타고니스트 |
| HRP20120712T1 (hr) | 2004-09-01 | 2012-10-31 | Gilead Sciences, Inc. | Postupak zarastanja rana primjenom antagonista adenozinskog a2b receptora |
| US7625881B2 (en) | 2005-06-16 | 2009-12-01 | Gilead Palo Alto, Inc. | Prodrugs of A2B adenosine receptor antagonists |
| WO2007109547A2 (en) | 2006-03-17 | 2007-09-27 | Cv Therapeutics, Inc. | Method of preventing and treating hepatic disease using a2b adenosine receptor antagonists |
-
2005
- 2005-10-14 EP EP10011664A patent/EP2311462A1/en not_active Withdrawn
- 2005-10-14 JP JP2007536923A patent/JP2008516969A/ja active Pending
- 2005-10-14 CN CNA200580034824XA patent/CN101039677A/zh active Pending
- 2005-10-14 WO PCT/US2005/036950 patent/WO2006044610A1/en not_active Ceased
- 2005-10-14 KR KR1020077008536A patent/KR20070063548A/ko not_active Ceased
- 2005-10-14 CA CA002583986A patent/CA2583986A1/en not_active Abandoned
- 2005-10-14 NZ NZ589657A patent/NZ589657A/en not_active IP Right Cessation
- 2005-10-14 US US11/251,450 patent/US20060159627A1/en not_active Abandoned
- 2005-10-14 MX MX2007004373A patent/MX2007004373A/es unknown
- 2005-10-14 AU AU2005295654A patent/AU2005295654B2/en not_active Ceased
- 2005-10-14 NZ NZ554485A patent/NZ554485A/en not_active IP Right Cessation
- 2005-10-14 RU RU2007117907/14A patent/RU2391103C2/ru not_active IP Right Cessation
- 2005-10-14 EP EP05808733A patent/EP1799221A1/en not_active Withdrawn
-
2007
- 2007-04-12 IL IL182493A patent/IL182493A0/en unknown
- 2007-05-14 NO NO20072466A patent/NO20072466L/no not_active Application Discontinuation
-
2009
- 2009-10-26 US US12/605,783 patent/US8466129B2/en active Active
-
2011
- 2011-12-19 JP JP2011277345A patent/JP2012056965A/ja not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030229103A1 (en) * | 2001-08-12 | 2003-12-11 | Klaus-Ulrich Weithmann | Pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides and the use thereof for selectively inhibiting collagenases |
| US20030139428A1 (en) * | 2001-11-09 | 2003-07-24 | Rao Kalla | A2B adenosine receptor antagonists |
| US20040176399A1 (en) * | 2001-11-09 | 2004-09-09 | Elfatih Elzein | A2B adenosine receptor antagonists |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006044610A1 (en) | 2006-04-27 |
| NO20072466L (no) | 2007-05-14 |
| AU2005295654A1 (en) | 2006-04-27 |
| US8466129B2 (en) | 2013-06-18 |
| CN101039677A (zh) | 2007-09-19 |
| EP1799221A1 (en) | 2007-06-27 |
| MX2007004373A (es) | 2007-08-08 |
| NZ554485A (en) | 2010-12-24 |
| RU2391103C2 (ru) | 2010-06-10 |
| JP2008516969A (ja) | 2008-05-22 |
| EP2311462A1 (en) | 2011-04-20 |
| CA2583986A1 (en) | 2006-04-27 |
| JP2012056965A (ja) | 2012-03-22 |
| US20100105706A1 (en) | 2010-04-29 |
| KR20070063548A (ko) | 2007-06-19 |
| US20060159627A1 (en) | 2006-07-20 |
| IL182493A0 (en) | 2007-09-20 |
| NZ589657A (en) | 2012-06-29 |
| RU2007117907A (ru) | 2008-11-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2005295654B2 (en) | Method of preventing and treating airway remodeling and pulmonary inflammation using A2B adenosine receptor antagonists | |
| AU2007227021B2 (en) | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists | |
| US20090137802A1 (en) | A2b adenosine receptor antagonists | |
| HK1156213A (en) | Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists | |
| AU2012261721A1 (en) | Method of preventing and treating hepatic disease using A2B adenosine receptor antagonists | |
| AU2011202523B2 (en) | A2B adenosine receptor antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: GILEAD SCIENCES, INC. Free format text: FORMER OWNER WAS: GILEAD PALO ALTO, INC. |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |